Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose
Crossref DOI link: https://doi.org/10.1007/s00280-023-04595-8
Published Online: 2023-09-29
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jessen, Bart A. http://orcid.org/0000-0002-9691-6931
Cornwell, Paul
Redmond, Sean
Visalli, Thomas
Lemper, Marie
Bunch, Todd
Hart, Timothy
Text and Data Mining valid from 2023-09-29
Version of Record valid from 2023-09-29
Article History
First Online: 29 September 2023